Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amylyx Pharmaceuticals Inc (AMLX – Research Report) and Nanosonics Limited (NNCSF – Research Report).
Amylyx Pharmaceuticals Inc (AMLX)
In a report released today, Corinne Johnson from Goldman Sachs reiterated a Buy rating on Amylyx Pharmaceuticals Inc. The company’s shares closed last Monday at $17.56.
According to TipRanks.com, Johnson is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $33.80 average price target, implying a 90.6% upside from current levels. In a report issued on February 23, H.C. Wainwright also maintained a Buy rating on the stock with a $42.00 price target.
See today’s best-performing stocks on TipRanks >>
Nanosonics Limited (NNCSF)
In a report released yesterday, Craig Wong-Pan from RBC Capital maintained a Hold rating on Nanosonics Limited, with a price target of $2.75. The company’s shares closed last Wednesday at $1.88, close to its 52-week low of $1.85.
According to TipRanks.com, Wong-Pan is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Nanosonics Limited with a $2.46 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMLX:
- Amylyx Pharmaceuticals, Inc.’s New Accounting & Financial Operations Risk – A Cause for Worry?
- Amylyx reports Q4 EPS 7c, consensus 23c
- SHAREHOLDER ALERT: Potential Recovery for Amylyx Pharmaceuticals, Inc. (AMLX) Investors
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Baird bullish on Amylyx, sees potential quadruple in shares
